We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Review of Current Systemic Therapy and Novel Systemic Therapy for Pancreatic Ductal Adenocarcinoma.
- Authors
Sarfraz, Humaira; Saha, Aditi; Jhaveri, Khushali; Kim, Dae Won
- Abstract
Background: This review aims to describe the systemic treatment options for pancreatic ductal adenocarcinoma and includes a summary of the current treatments as well as the ongoing clinical trials which may be efficacious in the treatment of this aggressive malignancy. Methods: A literature review was performed using MEDLINE/PubMed between August 1996 and February 2023. The reviewed studies are categorized into these categories: current standard of care treatments, targeted therapies, immunotherapy and clinical trials. The current treatment modality for the treatment of advanced pancreatic cancer is mainly systemic chemotherapy. Results: The introduction of polychemotherapy regimens including gemcitabine/nab-paclitaxel and FOLFIRINOX (oxaliplatin, irinotecan, folinic acid and fluorouracil) has improved the clinical outcome of advanced pancreatic cancer. For further improvement in clinical outcomes, several novel approaches have been extensively studied in pancreatic cancer. The review discusses the current standard chemotherapy regimen and the novel treatment options in the field. Conclusions: While there are novel treatments being explored for metastatic pancreatic, it remains a debilitating and aggressive disease with high mortality that warrants continued efforts to advance therapeutic options.
- Subjects
PANCREATIC duct; CANCER chemotherapy; LITERATURE reviews; PANCREATIC cancer; ADENOCARCINOMA; PANCREATIC intraepithelial neoplasia
- Publication
Current Oncology, 2023, Vol 30, Issue 6, p5322
- ISSN
1198-0052
- Publication type
Article
- DOI
10.3390/curroncol30060404